Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer

NCT02558868 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neoplasms

Interventions

DRUG: Irinotecan
DRUG: Oxaliplatin

Sponsor

Zhejiang University